PFA
LCTX icon

Paradigm Financial Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Paradigm Financial Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-17,100
Closed -$17K – 132
2019
Q3 		$17K Hold
17,100
– – 0.01% 126
2019
Q2 		$19K Hold
17,100
– – 0.01% 130
2019
Q1 		$22K Buy
17,100
+7,100
+71% +$8.83K 0.01% 123
2018
Q4 		$9K Sell
10,000
-1,430
-13% -$2.19K ﹤0.01% 128
2018
Q3 		$23K Buy
+11,430
New +$24K 0.01% 132

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Paradigm Financial Advisors's LCTX Position: Q4 2019 in Review

Paradigm Financial Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2019, closing a stake of 17,100 shares — an estimated $17K sold.

Paradigm Financial Advisors first reported a position in LCTX in Q3 2018 and held it in 5 quarters. The position peaked at $23K in Q3 2018. 108 funds tracked by Wall St. Rank hold LCTX as of Q4 2019.

  • Paradigm Financial Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Paradigm Financial Advisors sold 17,100 Lineage Cell Therapeutics shares in Q4 2019, an estimated $17K.
  • Paradigm Financial Advisors first reported a position in Lineage Cell Therapeutics in Q3 2018 and held it in 5 quarters.
  • Paradigm Financial Advisors's Lineage Cell Therapeutics position peaked at $23K in Q3 2018.
  • 108 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2019.

Based on Paradigm Financial Advisors's 13F filing for Q4 2019, filed 10 Feb 2020.